GleamWall
中文EN

CELU Celularity Inc

Pharmaceutical Preparations · Nasdaq · SEC CIK 1752828 · Fiscal year ends 12/31

Financial factors as of 2025-06-30 (2025Q2), TTM = sum of the last four quarters

Growth

TTM revenue YoY4.5%
TTM net income YoY34.7%
TTM EPS YoY43.2%
Revenue 3-yr CAGR21.0%
Net income 3-yr CAGR—

Margins

Gross margin55.1%
Operating margin-105.8%
Net margin-165.2%
FCF margin—
EBITDA margin-90.8%

Returns

ROE-6,367.2%
ROA-57.6%
ROIC (approx.)—
Asset turnover0.35x

Leverage & solvency

Liabilities / assets121.2%
Debt / equity—
Current ratio0.25x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.03x
Accruals ratio-55.6%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31
Income statement
Revenue$26.55M$54.22M
Cost of revenue$20.07M$14.99M
Gross profit$6.48M$39.23M
R&D expense$15.03M$17.39M
SG&A expense$51.27M$58.64M
Operating income-$61.31M-$38.36M
Pretax income-$91.71M-$57.89M
Income tax$3,000—
Net income-$91.72M-$57.89M
EBITDA-$54.01M-$30.44M
EPS (basic)-3.59-2.64
EPS (diluted)-3.59-2.64
Weighted avg. shares (diluted)25.60M21.89M
Balance sheet
Cash & equivalents$6.17M$10.98M
Receivables$4.65M—
Inventory$571,000$5.41M
Current assets$12.32M$20.56M
PP&E, net$55.80M$61.60M
Goodwill$7.35M$7.35M
Intangibles$7.76M$9.25M
Total assets$107.33M$132.68M
Current liabilities$80.76M$53.68M
Long-term debt$33.81M—
Total debt$33.81M—
Total liabilities$145.39M$123.84M
Shareholders' equity-$38.06M$8.84M
Net debt$27.64M—
Shares outstanding28.84M22.55M
Cash flow statement
Operating cash flow-$13.25M-$6.40M
Capital expenditure—$161,000
Free cash flow—-$6.56M
Investing cash flow—$514,000
Financing cash flow$18.65M$6.70M
Depreciation & amortization$7.29M$7.92M
Stock-based compensation$10.64M$11.57M

Free plan shows the latest 2 periods; Pro shows all 7 🔒

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.